Venous Thromboembolism Market Segments, Growth Drivers And Analysis – 2024

Spread the love

The venous thromboembolism global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Venous Thromboembolism Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The venous thromboembolism market size has grown steadily in recent years. It will grow from $2.33 billion in 2023 to $2.44 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to aging population, advancements in anticoagulants, reimbursement policies, increasing investments.
The venous thromboembolism market size is expected to see steady growth in the next few years. It will grow to $2.87 billion in 2028 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to global healthcare access, genetic risk assessment, telemedicine and remote monitoring, patient education and support. Major trends in the forecast period include extended thromboprophylaxis, novel oral anticoagulants, personalized treatment plans, advanced diagnostic imaging.
Order your report now for swift delivery @
Scope Of Venous Thromboembolism Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Venous Thromboembolism Market Overview
Market Drivers –
The expansion of the healthcare infrastructure is expected to propel the growth of the venous thromboembolism market going forward. The healthcare industry refers to amalgamating and integrating the economic system’s sectors that offer products and services for curing, preventing, rehabilitating and providing palliative care for patients. The expansion of the healthcare industry contributes to the development of Institutional infrastructure, policies, practices and educational programs necessary to support the implementation of VTE prevention protocols. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the US increased to 6,129 from 6,093 in 2022. Furthermore, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2020 and 2021, healthcare spending in the UK increased by 9.4% in nominal terms and 9.7% in real terms. Therefore, the expansion of the healthcare industry is driving the growth of the venous thromboembolism market.
Market Trends –
Major companies operating in the venous thromboembolism market are developing novel anticoagulant drugs and solutions to sustain their position in the market. Anticoagulant advancements can lead to the development of more effective drugs that can prevent or cure venous thromboembolism. For instance, in September 2022, Anthos Therapeutics, a US-based clinical-stage biotherapeutics company, received regulatory approval for its abelacimab anticoagulant medicine from the Food and Drug Administration (FDA), a US-based government agency. The new medicine is a fully human monoclonal antibody and is indicated for preventing stroke and systemic embolism in patients with atrial fibrillation. The newly developed, once-monthly, dual-acting antibody abelacimab is intended to cause hemostasis-sparing anticoagulation by inhibiting Factor XI.
The venous thromboembolism market covered in this report is segmented –
1) By Type: Deep Vein Thrombosis; Pulmonary Embolism; Other Types
2) By Treatment: Anti-Clotting Medications; Mechanical Devices; Thrombolytic Therapy; Other Treatment
3) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users
Get an inside scoop of the venous thromboembolism market, Request now for Sample Report @
Regional Insights –
North America was the largest region in the venous thromboembolism market in 2023. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major players in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.
Table of Contents
1. Executive Summary
2. Venous Thromboembolism Market Report Structure
3. Venous Thromboembolism Market Trends And Strategies
4. Venous Thromboembolism Market – Macro Economic Scenario
5. Venous Thromboembolism Market Size And Growth
…..
27. Venous Thromboembolism Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Follow Us On:

Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →